Oculis Holding AG filings document its reporting as a Swiss foreign private issuer and its development-stage biopharmaceutical business in ophthalmology and neuro-ophthalmology. Form 6-K reports furnish IFRS consolidated financial statements, interim financial statements, management discussion and analysis, annual reports, press releases, annual general meeting invitations, proxy materials, and current company updates.
The filing record also covers ordinary-share capital structure, registration statement references on Form F-3 and Form S-8, at-the-market offering arrangements, sales agreements, incorporation by reference, shareholder voting matters, and governance materials. Clinical and regulatory disclosures relate to OCS-01, Privosegtor, Licaminlimab, related development programs, liquidity, operating expenses, and the risks associated with advancing investigational drug candidates.
Oculis Holding AG suspended and terminated its at-the-market prospectus that permitted sales of up to $100 million of ordinary shares under its May 8, 2024 sales agreement with Leerink Partners. As of this report, no shares were sold under the ATM prospectus. The underlying sales agreement remains in effect, and any future sales would require a new prospectus, prospectus supplement or registration statement.
Oculis Holding AG (OCS) filed a Form 144 reporting a proposed sale of 7,460 common shares, with an aggregate market value of $148,230.20, to be sold on 10/09/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The filer reports the shares were acquired and paid for on 10/09/2025 through an exercise of stock options and that payment was made in cash. The filing notes 43,662,402 shares outstanding and states there were no sales in the past three months by the same person. The notice includes the standard signature representation about no undisclosed material adverse information.
Oculis Holding AG (OCS) announced initiation of the PIONEER clinical program for Privosegtor, a candidate to treat acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION). The program comprises three concurrent pivotal trials: PIONEER-1 beginning in Q4 2025 for AON, PIONEER-2 in the first half of 2026 measuring low-contrast visual acuity at 3 months, and PIONEER-3 in mid-2026 for NAION. PIONEER-2 will mirror dosing and enrollment from the positive Phase 2 ACUITY trial. Running the trials together is expected to create operational synergies, cost efficiencies, and accelerate timelines. The filing references accompanying press materials dated October 6, 2025.
Oculis Holding AG filing reports a proposed sale of 25,000 common shares through UBS Financial Services on 09/23/2025, with an aggregate market value of $442,500 based on the notice. The filing shows 43,662,402 shares outstanding. The shares were acquired on 03/02/2023 as issuance of earnout shares from the issuer and fully paid on that date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that the seller is unaware of any undisclosed material adverse information.
Oculis Holding AG filed a Form 6-K to furnish its unaudited financial information for the three and six month periods ended June 30, 2025. The submission points investors to attached interim condensed consolidated financial statements and a Management’s Discussion and Analysis that explain the company’s financial condition and operating results over this mid‑year period.
The company also attached a related press release dated August 21, 2025. The financial statements and MD&A are incorporated by reference into existing Form S-8 and Form F-3 registration statements, linking these updated results to Oculis Holding’s ongoing equity compensation and potential securities offerings.